Discovering DAB2IP: A Potential Drug Target and Biomarker (G153090)

Target Name: DAB2IP

NCBI ID: G153090

DAB2IP

Discovering DAB2IP: A Potential Drug Target and Biomarker

DAB2IP (AF9Q34) is a drug target and a potential biomarker for various diseases, including cancer. It is a protein that is expressed in various tissues and organs, including the brain, pancreas, and gastrointestinal tract.

The discovery of DAB2IP was made through a screening process for potential drug targets using the Affymet Biotechnology library. This process involved the use of a computer algorithm to identify potential protein targets that were expressed in a wide range of tissues and organs. The algorithm identified DAB2IP as a potential drug target due to its unique expression pattern across various tissues and organs.

DAB2IP is a transmembrane protein that is expressed in the brain, pancreas, and gastrointestinal tract. It is involved in the regulation of various cellular processes, including cell signaling, neurotransmitter signaling, and cell adhesion. DAB2IP has been shown to be involved in several diseases, including cancer.

One of the main challenges in the study of DAB2IP is its complex structure. DAB2IP is a transmembrane protein that spans the entire cell membrane and consists of multiple domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The transmembrane domain is the region of the protein that is involved in its interactions with other molecules, including other proteins and drugs.

In order to study the function of DAB2IP, researchers used a variety of techniques, including biochemical, cellular, and mass spectrometry. These studies have provided valuable information about the structure and function of DAB2IP.

One of the key findings from these studies is that DAB2IP is involved in several signaling pathways, including the TGF-β pathway and the Wnt pathway. The TGF-β pathway is a well-known signaling pathway that is involved in the regulation of cellular growth and differentiation, while the Wnt pathway is a signaling pathway that is involved in the regulation of cell adhesion and development.

In addition to its involvement in these signaling pathways, DAB2IP has also been shown to be involved in the regulation of neurotransmitter signaling. This suggests that DAB2IP may be a potential drug target for diseases that are characterized by disruptions in neurotransmitter signaling, such as depression and anxiety.

Another potential application of DAB2IP is its potential as a biomarker for cancer. Cancer is a disease that is characterized by the uncontrolled growth and proliferation of cells. The regulation of cellular processes, including cell signaling and neurotransmitter signaling, is critical for the growth and survival of cancer cells. As such, DAB2IP may be a useful biomarker for the diagnosis and treatment of cancer.

In conclusion, DAB2IP is a drug target and a potential biomarker for various diseases, including cancer. Its unique expression pattern across various tissues and organs, as well as its involvement in several signaling pathways, make it an attractive target for drug development. Further research is needed to fully understand the function of DAB2IP and its potential as a drug and biomarker.

Protein Name: DAB2 Interacting Protein

Functions: Functions as a scaffold protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Involved in several processes such as innate immune response, inflammation and cell growth inhibition, apoptosis, cell survival, angiogenesis, cell migration and maturation. Also plays a role in cell cycle checkpoint control; reduces G1 phase cyclin levels resulting in G0/G1 cell cycle arrest. Mediates signal transduction by receptor-mediated inflammatory signals, such as the tumor necrosis factor (TNF), interferon (IFN) or lipopolysaccharide (LPS). Modulates the balance between phosphatidylinositol 3-kinase (PI3K)-AKT-mediated cell survival and apoptosis stimulated kinase (MAP3K5)-JNK signaling pathways; sequesters both AKT1 and MAP3K5 and counterbalances the activity of each kinase by modulating their phosphorylation status in response to pro-inflammatory stimuli. Acts as a regulator of the endoplasmic reticulum (ER) unfolded protein response (UPR) pathway; specifically involved in transduction of the ER stress-response to the JNK cascade through ERN1. Mediates TNF-alpha-induced apoptosis activation by facilitating dissociation of inhibitor 14-3-3 from MAP3K5; recruits the PP2A phosphatase complex which dephosphorylates MAP3K5 on 'Ser-966', leading to the dissociation of 13-3-3 proteins and activation of the MAP3K5-JNK signaling pathway in endothelial cells. Mediates also TNF/TRAF2-induced MAP3K5-JNK activation, while it inhibits CHUK-NF-kappa-B signaling. Acts a negative regulator in the IFN-gamma-mediated JAK-STAT signaling cascade by inhibiting smooth muscle cell (VSMCs) proliferation and intimal expansion, and thus, prevents graft arteriosclerosis (GA). Acts as a GTPase-activating protein (GAP) for the ADP ribosylation factor 6 (ARF6) and Ras. Promotes hydrolysis of the ARF6-bound GTP and thus, negatively regulates phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent TLR4-TIRAP-MyD88 and NF-kappa-B signaling pathways in endothelial cells in response to lipopolysaccharides (LPS). Binds specifically to phosphatidylinositol 4-phosphate (PtdIns4P) and phosphatidylinositol 3-phosphate (PtdIns3P). In response to vascular endothelial growth factor (VEGFA), acts as a negative regulator of the VEGFR2-PI3K-mediated angiogenic signaling pathway by inhibiting endothelial cell migration and tube formation. In the developing brain, promotes both the transition from the multipolar to the bipolar stage and the radial migration of cortical neurons from the ventricular zone toward the superficial layer of the neocortex in a glial-dependent locomotion process. Probable downstream effector of the Reelin signaling pathway; promotes Purkinje cell (PC) dendrites development and formation of cerebellar synapses. Functions also as a tumor suppressor protein in prostate cancer progression; prevents cell proliferation and epithelial-to-mesenchymal transition (EMT) through activation of the glycogen synthase kinase-3 beta (GSK3B)-induced beta-catenin and inhibition of PI3K-AKT and Ras-MAPK survival downstream signaling cascades, respectively

The "DAB2IP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAB2IP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets